LUMO Lumos Therapeutics: Price-to-Projected Revenue Ratio

Lumos Pharma, Inc. - graphic logo of issuer LUMO

The forward revenue multiple reflects the dynamics of a biotech company whose operations rely on patents within the US rare metabolic pathology niches. 16.90 captures the value of this parameter. The competitive advantage of Lumos Pharma, Inc. (LUMO) lies in replacing pediatric injections with convenient tablets for endocrine disorders. Stable management is currently focusing on the commercialization of its primary R&D candidate, maintaining shareholder confidence following successful trials.

Lumos Pharma - LUMO Market Cap to Expected Sales Ratio (period 07/04/2022 - 12/21/2024)

Summary analytical data breakdowns for lumos-pharma.com (LUMO)

- market price and analyst price targets:
Summary company analytics:Lumos Pharma Inc (LUMO)
Original product of Lumos Pharma, Inc.

Forward P/S determines investment attractiveness by comparing current market capitalization with projected revenue to identify overpayment for future success. By analyzing this forward price-to-sales chart, an investor assesses the sustainability of the premium on the assets of Lumos Pharma, Inc. (LUMO), whose market value is supported by exceptional patent barriers and orphan drug status, which minimize competitive risks during therapy development.

Competitors of Lumos Pharma, Inc.

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Market Cap to Future Revenue Ratio|BMEA: Forward Price-to-Revenue Multiple|Forward Price to Sales QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Forward Price-to-Revenue Multiple|vTv Therapeutics, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Agape ATP Corp.|Forward Price-to-Revenue Multiple Pluri (PLUR)|Forward P/S Multiple SYBX|Market Cap to Expected Sales Ratio Lipocine Inc|Price-to-Projected Revenue Ratio Matinas BioPharma Holdings MTNB|Market Cap to Expected Sales Ratio Spruce Biosciences (SPRB)|GLTO: Forward Price-to-Revenue Multiple|Future Price to Revenue CTCX|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio